Christopher Degnan
2020
In 2020, Christopher Degnan earned a total compensation of $1.5M as Chief Financial Officer at Galera Therapeutics, a 35% decrease compared to previous year.
Compensation breakdown
| Bonus | $70,000 |
|---|---|
| Non-Equity Incentive Plan | $174,800 |
| Option Awards | $822,393 |
| Salary | $380,000 |
| Other | $11,400 |
| Total | $1,458,593 |
Degnan received $822.4K in option awards, accounting for 56% of the total pay in 2020.
Degnan also received $70K in bonus, $174.8K in non-equity incentive plan, $380K in salary and $11.4K in other compensation.
Rankings
In 2020, Christopher Degnan's compensation ranked 6,950th out of 13,090 executives tracked by ExecPay. In other words, Degnan earned more than 46.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,950 out of 13,090 | 47th |
Division Manufacturing | 2,894 out of 5,621 | 49th |
Major group Chemicals And Allied Products | 1,169 out of 2,254 | 48th |
Industry group Drugs | 1,007 out of 1,954 | 49th |
Industry Pharmaceutical Preparations | 751 out of 1,459 | 49th |
Source: SEC filing on April 28, 2022.
Degnan's colleagues
We found one more compensation record of an executive who worked with Christopher Degnan at Galera Therapeutics in 2020.
2020
J Sorensen
Galera Therapeutics
Chief Executive Officer
News
Galera Therapeutics CEO J Sorensen's 2023 pay slips 8% to $1.3M
January 24, 2025
Galera Therapeutics CEO J Sorensen's 2022 pay falls 46% to $1.4M
April 27, 2023
Galera Therapeutics CEO J Sorensen's 2021 pay slips 14% to $2.5M
April 28, 2022
Galera Therapeutics CEO J Sorensen's 2019 pay jumps 373% to $2.5M
April 27, 2020